Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 clients • 6 examiners • 5 art units • 0 of 6 (0%) have an AI response strategy ready
Prosyla Group PC focuses on Biotechnology & Pharmaceuticals, with 351 career applications. The firm maintains a resolved allowance rate of 85.09 percent. This success is achieved through an average of 4.15 office actions per allowance, suggesting a persistent approach to prosecution. The firm currently has 5 pending office actions.
The 85.09 percent allowance rate is a strong indicator of success in the Biotechnology & Pharmaceuticals sector. However, the 4.15 office actions per allowance suggest that clients should expect a longer prosecution process involving several interactions with the patent office. For the 351 career applications filed, these figures demonstrate the firm's ability to eventually secure grants despite a rigorous examination cycle.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (50%) |
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| RICCI, CRAIG D | 1 | 53.5% | +52.7% |
| BALLARD, KIMBERLY | 1 | 53.7% | +49.0% |
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
| BROWN, MINDY G | 1 | 55.9% | +44.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | SALMON, KATHERINE D | 9d |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | BROWN, MINDY G | 13d |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | SALMON, KATHERINE D | 9d |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | BROWN, MINDY G | 13d |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | — |
| 18792473 | EXOSOME COMPOSITION CONTAINING GANODERMA IMMUNOMODULATORY PROTEIN AND USES THEREOF | RICCI, CRAIG D | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Mycomagic Biotechnology Co., Ltd. | 2 |
| EG BIOMED CO., LTD. | 1 |
| Future Pharmtech Inc. | 1 |
| National Health Research Institutes | 1 |
| Academia Sinica | 1 |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1611 | 1 |
| 1675 | 1 |
| 1600 | 1 |
| 1681 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | Eg Biomed Co., Ltd. | SALMON, KATHERINE D | 1682 | §101§103 | Non-Final OA | 9d | Pending | Dec 11, 2024 |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | Future Pharmtech Inc. | NESTOR, DONNA MICHELLE | §103§112 | Non-Final OA | — | Pending | Aug 07, 2024 | |
| 18792473 | EXOSOME COMPOSITION CONTAINING GANODERMA IMMUNOMODULATORY PROTEIN AND USES THEREOF | Mycomagic Biotechnology Co., Ltd. | RICCI, CRAIG D | 1611 | §103 | Final Rejection | — | Pending | Aug 01, 2024 |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | National Health Research Institutes | BALLARD, KIMBERLY | 1675 | §101§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17821291 | IMMUNOMODULATORY PROTEIN FOR PREVENTION OF CORONAVIRUS INFECTION | Mycomagic Biotechnology Co., Ltd. | SPAINE, ROBERT FRANKLIN | 1600 | §112Other | Non-Final OA | — | Pending | Aug 22, 2022 |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | Academia Sinica | BROWN, MINDY G | 1681 | §101§112 | Non-Final OA | 13d | Pending | Jun 14, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial